AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 141 min read$MAIA

Guerrero Ramiro purchased $50K of MAIA

Guerrero Ramiro purchased 37,595 shares of MAIA Biotechnology, Inc. (MAIA) at $1.32 on 2026-09-10.

Original reporting
SEC EDGAR · Guerrero Ramiro
Published Sep 14, 2026, 1:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 14, 2026, 1:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$MAIA
Neutral
medium confidence
Mentioned
$MAIA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MAIANeutralLow
01

Why it matters

The transaction is a primary disclosure but small in scale, offering limited trading insight.

02

Market read

Minor insider buy; unlikely to move the stock significantly.

03

What to watch

Potential upcoming clinical data or financing events not disclosed.

Relevance 4/10Novelty 5/10Timing: filed today

Background

SEC Form 4 filing discloses insider transactions. Director purchases are publicly reported.

Company-level read

Ticker impact

$MAIANeutralMedium confidence
Context

Director Guerrero Ramiro bought 37,595 shares of MAIA for $49.5K, increasing his stake to 773,296 shares.

Expected impact

Minor upward pressure, likely negligible on market price.

Evidence & confidence

Purchase size is modest relative to float; director buying is a positive signal but not material.

Market effects

Sector

None significant for biotech sector.

Regional

No regional effect.

Global

Limited to MAIA shareholders.

Counterpoint

What could challenge this read

Insider purchase could be routine portfolio rebalancing, not a strong buy signal.

Key entities

  • Company
    MAIA Biotechnology, Inc.

    Biotech firm listed on NASDAQ.

  • Insider
    Guerrero Ramiro

    Director of MAIA who purchased shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MAIA insider trading history →

Related articles

SEP 16
$MAIAMedAI 8/10

MAIA Biotechnology, Inc.: MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial

MAIA Biotechnology, Inc. (NYSE American: MAIA) dosed the first U.S. patient in its Phase 2 THIO-101 trial for ateganosine in third-line non-small cell lung cancer (NSCLC). The trial is funded by a $2.3 million NIH grant. Ateganosine has FDA Fast Track designation and showed promising overall survival data in prior trials.

finanznachrichten.de2 min
SEP 2
$UPCMed

6 After-Hours Healthcare Gainers: Universe Pharma, BioAffinity, Modular Medical, Telix Pharma & More

Universe Pharmaceuticals (UPC) rose 34.89% after-hours due to multiple Schedule 13G filings. BioAffinity (BIAF) explores new uses for its CyPath Lung test, up 3%. Modular Medical (MODD) gained 7% after announcing a product launch. MAIA (MAIA) rose 6% following an insider purchase. Telix (TLX) completed a Phase 3 study, up 2.21%. aTyr Pharma (ATYR) awaits FDA response, up 4%.

rttnews.com2 min
JUL 8
$MAIAMedAI 8/10

MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial

MAIA Biotechnology (NYSE American: MAIA) reported initial Phase 2 THIO-101 Part C data in third-line advanced NSCLC. Ateganosine followed by cemiplimab (Libtayo) produced a 90.5% disease control rate (19/21) in 3L patients, compared with 25-35% for standard chemotherapy. MAIA said safety is acceptable and enrollment is completed internationally.

manilatimes.net2 min